Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2018-07-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OrthoPureXT Multiligament PMCF Study
NCT05655156
Stereo Radiography of TKA Patella Mechanics
NCT02532933
Triathlon All-Polyethylene Tibia Outcomes Study
NCT04636190
Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive/Osteoinductive Compound
NCT04993339
Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System
NCT02175576
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Pilot Safety Study. The primary objective of this study is to evaluate the clinical safety of the OrthoPure™ XT device in a small group of patients that require reconstruction of the Anterior Cruciate Ligament (ACL) due to partial or complete tear of the ACL.
Clinical safety will be analyzed through measurement of immune response (alpha-Gal IgG), blood and urine analysis, incidence of secondary surgical interventions with the treated knee, and the incidence of individual adverse events.
The second objectives of this study are to assess the efficacy endpoints, specifically: improvement in knee stability, function and pain; improvement in patient quality of life and radiographic analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
OrthoPure™ XT
A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OrthoPure™ XT
A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who have been diagnosed with a partial or complete tear of the ACL as determined by MRI, require surgical reconstruction of the ACL, and are candidates for ACL surgery.
3. Patients who have passive flexion ≥ 120°, and passive extension on the target knee is the same as the contralateral knee, in the judgment of the Investigator.
4. Patients who have Medial Collateral Ligament (MCL) injury of Grade 2 or less.
5. Patients with osteoarthritis of Grade 2 or less as defined radiographically on the Kellgren-Lawrence (K-L) scale.
6. Patients who are able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study.
7. Patients who are willing and able to comply with all study procedures including all pre-operative, post-operative and rehabilitation requirements.
8. If female and of child-bearing potential, patients who have a negative urine pregnancy test at Visit 2 and have no intention to become pregnant in the next 24 months.
Exclusion Criteria
2. Patients presenting with osteoarthritis of the target knee e.g. International Cartilage Repair Society (ICRS) Grade III or higher as determined by their baseline MRI scan.
3. Patients who have had previous ACL reconstruction on the target knee.
4. Patients who have had any other type of surgical procedure on the target knee in the 3 months prior to Visit 1.
5. Patients with ligament instability, osteoarthritis greater than Grade 2 or a current ACL injury in the contralateral knee.
6. Patients with a complete or partial Lateral Collateral Ligament (LCL) tear or Posterior Cruciate Ligament (PCL) tear on the target knee.
7. Patients with meniscal repairs and tears requiring more than one third (1/3) removal of the meniscus on the target knee as determined during knee arthroscopy.
8. Patients who have an active systemic infection, or an active local infection in or near the target knee, or have a previous history of joint infection.
9. Patients who are participating concurrently in another clinical trial, or have participated in a clinical trial within the last 90 days, or intend to during the course of the study.
10. Patients who have previously been implanted with any type of xenograft device.
11. Patients with known immunodeficiency including patients who are receiving or have received corticosteroids, immunosuppressants, immunostimulating agents or radiation therapy within 6 months of Visit 1.
12. Patients who have conditions that may be exacerbated by, or may interfere with the results of the skin prick test.
13. Patients with significant comorbidities or conditions associated with high risk for surgical or anesthetic survival (e.g. renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.).
14. Patients with active neoplastic disease.
15. Patients with known allergy to mammalian meat, porcine products or a religious objection to the use of implanted porcine material.
16. Patients with current drug or alcohol abuse, or a history of the same within the last 6 months.
17. Patients with local circulatory problems, (e.g. thrombophlebitis and lymphedema).
18. Patients with any mental or psychological disorder that would impair their ability to complete the study questionnaires.
19. Patients with any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the patient unable to perform appropriate postoperative rehabilitation.
20. Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance.
\-
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TRX Orthopedics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tom Carter
Role: PRINCIPAL_INVESTIGATOR
St. Joseph's Outpatient Surgery Center
Jack Farr
Role: PRINCIPAL_INVESTIGATOR
OrthoIndy Hospital South
David Caborn
Role: PRINCIPAL_INVESTIGATOR
Jewish Hospital and St. Mary's Healthcare
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St.Joseph's Outpatient Surgery Center
Phoenix, Arizona, United States
OrthoIndy Hospital South
Greenwood, Indiana, United States
Jewish Hospital
Louisville, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRG-A02/0021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.